Journal article
Early Mortality in a Multinational Systemic Sclerosis Inception Cohort
Yanjie Hao, Marie Hudson, Murray Baron, Patricia Carreira, Wendy Stevens, Candice Rabusa, Solene Tatibouet, Loreto Carmona, Beatriz E Joven, Molla Huq, Susanna Proudman, Mandana Nikpour
ARTHRITIS & RHEUMATOLOGY | WILEY | Published : 2017
DOI: 10.1002/art.40027
Abstract
OBJECTIVE: To determine mortality and causes of death in a multinational inception cohort of subjects with systemic sclerosis (SSc). METHODS: We quantified mortality as standardized mortality ratio (SMR), years of life lost, and percentage mortality in the first decade of disease. The inception cohort comprised subjects recruited within 4 years of disease onset. For comparison, we used a prevalent cohort, which included all subjects irrespective of disease duration at recruitment. We determined a single primary cause of death (SSc related or non-SSc related) using a standardized case report form, and we evaluated predictors of mortality using multivariable Cox regression. RESULTS: In the inc..
View full abstractGrants
Awarded by Canadian Institutes of Health Research
Awarded by Spanish Ministry of Science and Innovation (FIS grant)
Awarded by National Health and Medical Research Council of Australia
Funding Acknowledgements
Supported by Scleroderma Australia, Arthritis Australia, Actelion Australia, Bayer, CSL Biotherapies, GlaxoSmithKline Australia, and Pfizer. The Canadian Scleroderma Research Group (CSRG) is supported by the Canadian Institutes of Health Research (grant FRN 83518), the Scleroderma Society of Canada and its provincial chapters, Scleroderma Society of Ontario, Scleroderma Society of Saskatchewan, Sclerodermie Quebec, Cure Scleroderma Foundation, INOVA Diagnostics, Inc., Dr. Fooke Laboratorien GmbH, Euroimmun, Mikrogen GmbH, Fonds de la recherche en sante du Quebec, the Canadian Arthritis Network, and Jewish General Hospital and Lady Davis Research Institute, Montreal, Quebec, Canada. The CSRG has also received educational grants from Pfizer and Actelion Pharmaceuticals. The Madrid University Hospital 12 de Octubre Scleroderma Cohort Study was supported by the Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (FIS grant PI11/0156). Dr. Nikpour's work was supported by the National Health and Medical Research Council of Australia (fellowship APP1071735).